Abstract
Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 113-115 |
| Number of pages | 3 |
| Journal | Investigational New Drugs |
| Volume | 20 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2002 |
| Externally published | Yes |
Fingerprint
Keywords
- Amonafide
- Central nervous system tumors
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Cite this
Phase II trial of amonafide in central nervous system tumors : A Southwest Oncology Group Study. / Taylor, Sarah A.; Rankin, Cathryn; Townsend, Jeannette J.; Craig, Johnny B.; Vance, Ralph B.; Solank, Dilip L.; Brown, Thomas D.; Jaeckle, Kurt.
In: Investigational New Drugs, Vol. 20, No. 1, 2002, p. 113-115.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial of amonafide in central nervous system tumors
T2 - A Southwest Oncology Group Study
AU - Taylor, Sarah A.
AU - Rankin, Cathryn
AU - Townsend, Jeannette J.
AU - Craig, Johnny B.
AU - Vance, Ralph B.
AU - Solank, Dilip L.
AU - Brown, Thomas D.
AU - Jaeckle, Kurt
PY - 2002
Y1 - 2002
N2 - Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.
AB - Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.
KW - Amonafide
KW - Central nervous system tumors
UR - http://www.scopus.com/inward/record.url?scp=0036204930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036204930&partnerID=8YFLogxK
U2 - 10.1023/A:1014488922368
DO - 10.1023/A:1014488922368
M3 - Article
C2 - 12003186
AN - SCOPUS:0036204930
VL - 20
SP - 113
EP - 115
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 1
ER -